Inhibition of microparticle release triggers endothelial cell apoptosis and detachment

Summary

Endothelial cell cultures contain caspase 3-containing microparticles (EMP), which are reported to form during or after cell detachment. We hypothesize that also adherent endothelial cells release EMP, thus protecting these cells from caspase 3 accumulation, detachment and apoptosis. Human umbilical vein endothelial cells (HUVEC) were incubated with and without inhibitors of microparticle release (Y-27632,calpeptin), both in the absence or presence of additional “external stress”, i.e. the apoptotic agent staurosporin (200 nM) or the activating cytokine interleukin (IL)-1α (5 ng/ml). Control cultures contained mainly viable adherent cells and minor fractions of apoptotic detached cells and microparticles in the absence of inhibitors. In the presence of inhibitors, caspase 3 accumulated in adherent cells and detachment tended to increase. During incubation with either staurosporin or IL-1α in the absence of inhibitors of microparticle release, adherent cells remained viable, and detachment and EMP release increased slightly. In the presence of inhibitors, dramatic changes occurred in staurosporin-treated cultures. Caspase 3 accumulated in adherent cells and >90% of the cells detached within 48 hours. In IL-1α-treated cultures no accumulation of caspase 3 was observed in adherent cells, although detachment increased. Scanning electron microscopy studies confirmed the presence of EMP on both adherent and detached cells. Prolonged culture of detached cells indicated a rapid EMP formation as well as some EMP formation at longer culture periods. Inhibition of EMP release causes accumulation of caspase 3 and promotes cell detachment, although the extent depends on the kind of “external stress”. Thus, the release of caspase 3-containing microparticles may contribute to endothelial cell survival.

Keywords

Apoptosis - microparticles - endothelial cells

^* Both authors contributed equally to this manuscript.

• References

• 1 Danesh J, Whincup P, Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000; 321: 199-204.
• 2 Laaksonen DE, Niskanen L, Nyyssonen K. et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-1410.
• 3 Rutter MK, Meigs JB, Sullivan LM. et al. C-reactive protein, the metabolic syndrome, and the prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.
• 4 Ridker PM, Buring JE, Cook NR. et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-397.
• 5 Ishikawa S, Kayaba K, Gotoh T. et al. Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ J 2007; 71: 26-31.
• 6 Festa A, D´Agostino Jr R, Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
• 7 Timpson NJ, Lawlor DA, Harbord RM. et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366: 1954-1959.
• 8 Yudkin JS, Stehouwer CD, Emeis JJ. et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
• 9 Sung KC, Suh JY, Kim BS. et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429-433.
• 10 Ford ES, Giles WH, Myers GL. et al. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Clin Chem 2003; 49: 1353-1357.
• 11 Ford ES, Giles WH, Mokdad AH. et al. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004; 50: 574-581.
• 12 Carlson CS, Aldred SF, Lee PK. et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77.
• 13 Pankow JS, Folsom AR, Cushman M. et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681-689.
• 14 Wessel J, Moratorio G, Rao F. et al. C-reactive protein, an "intermediate" phenotype, for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/ beta-adrenergic pathway loci. J Hypertension 2007; 25: 329-343.
• 15 Suk HJ, Ridker PM, Cook NR. et al. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005; 178: 139-145.
• 16 Kovacs A, Green F, Hansson LO. et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005; 178: 193-198.
• 17 Brull DJ, Serrano N, Zito F. et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23: 2063-2069.
• 18 Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med 2005; 56: 303-320.
• 19 Szalai AJ, Wu J, Lange EM. et al. Single-nucleotide polymorphisms in the C- reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005; 83: 440-447.
• 20 Martínez-Larrad MT, Fernández-Pérez C, González-Sánchez JL. et al. Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia. Med Clin (Barc) 2005; 125: 481-486.
• 21 American Diabetes Association.. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2007; 30: S42-47.
• 22 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419.
• 23 Gabriel SB, Schaffner SF, Nguyen H. et al. (2002). The estructure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
• 24 Treoguet DA, Escolano S, Tiret L. A new algorith for haplotype-based association analysis: the Stochastic- EM algorithm. Ann Human Gen 2004; 68: 165-177.
• 25 Kathiresan S, Larson MG, Vasan RS. et al. Contribution of clinical correlates and 13 C-Reactive Protein gene polymorphisms to the interindividual variability in serum C-reactive protein levels. Circulation 2006; 113: 1415-1423.
• 26 Crawford DC, Sanders CL, Qin X. et al. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006; 114: 2458-2465.
• 27 Hutchinson WL, Coll AP, Gallimore JR. et al. Is leptin an important physiological regulator of CRP?. Nat Med 2007; 13: 17-18.
• 28 Farooqui IS, O´Rahilly S. Is leptin an important physiological regulator of CRP?. Nat Med 2007; 13: 16-17.
• 29 Gertler A, Niv-Spector L, Reicher S. Is leptin an important physiological regulator of CRP?. Nat Med 2007; 13: 18-19.
• 30 Zhao A. Is leptin an important physiological regulator of CRP?. Nat Med 2007; 13: 20-21.
• 31 Shamsuzzaman AS, Winnicki M, Wolk R. et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181-2185.
• 32 Ble A, Windham G, Bandinelli S. et al. Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti Study). Am J Cardiol 2005; 96: 991-995.
• 33 Chen K, Li F, Li J. et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006; 12: 425-432.
• 34 Van Dielen FMH, vanșt Veer C, Schols AM. et al. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obesity 2001; 25: 1759-1766.
• 35 Gómez-Ambrosi J, Salvador J, Silva C. et al. Increased cardiovascular risk markers in obesity are associated with body adiposity: role of leptin. Thromb Haemost 2006; 95: 991-996.
• 36 Chan JL, Bullen J, Stoyneva V. et al. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab 2005; 90: 1618-1624.
• 37 Hukshorn CJ, Lindeman JH, Toet KH. et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 2004; 89: 1773-1778.
• 38 Crawford DC, Yi Q, Smith JD. et al. Allelic spectrum of the natural variation in CRP. Hum Genet 2006; 119: 496-504.
• 39 Lekakis JP, Ikonomidis I, Tsibida M. et al. Genetic variations of the endothelial nitric oxide synthase gene are related to increased levels of C- reactive protein and macrophage-colony stimulating-factor in patients with coronary artery disease. Thromb Haemost 2006; 96: 520-528.
• 40 Eklund C, Jahan F, Pessi T. et al. IL1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw 2003; 14: 168-171.
• 41 Russell AI, Cunninghame Graham DS, Shepherd C. et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-147.
• 42 Lange LA, Carlson CS, Hindorff LA. et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. J Am Med Assoc 2006; 296: 2703-2711.